Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Myeloma: Update Bulletin #1 [September 2018]

Product Code:
Publication Date:
September 2018

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the multiple myeloma (MM) market, including: the extension of Genmab/Janssen Biotech’s EU marketing authorisation for Darzalex (daratumumab) to include the first-line treatment of patients with MM who are transplant ineligible, in combination with Velcade, melphalan and prednisone (VMP);Takeda reporting positive results from the Phase III TOURMALINE-MM3 trial of Ninlaro (ixazomib) as single-agent, post-transplant maintenance therapy; and positive long-term data from the Phase III GIMEMA-MMY-3006study investigating overall survival benefits of the addition of Takeda/Janssen’s Velcade to thalidomide and dexamethasone therapy.

Business Questions:

• What is the immediate reaction from KOLs to the extension of the EU marketing authorisation for Darzalex to include the first-line treatment of transplant-ineligible multiple myeloma in combination with VMP?
• How do KOLs view the risk/benefit profile of the Darzalex and VMP quadruplet therapy?
• How will differences in current treatment pathways in Europe versus the US, affect uptake of Darzalex in combination with VMP in the first-line setting?
• On current evidence, do KOLs expect Ninlaro to compete effectively with Revlimid in the post-transplant maintenance setting?
• Where do experts see Ninlaro being of most use in post-transplant maintenance treatment?
• How relevant are the results from the GIMEMA-MMY-3006 trial, of Velcade in combination with thalidomide and dexamethasone, and will they alter treatment practice?


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved